Meta-analysis suggests idarucizumab-enabled thrombolysis is feasible for dabigatran-treated stroke patients after AF ablation.
Reversing blood thinners may allow stroke treatment with good safety and recovery.
This meta-analysis and case report review examines idarucizumab-enabled intravenous thrombolysis in dabigatran-treated patients with peripro…
Reversing dabigatran before stroke treatment appears safe, showing low bleeding and death rates with recovery similar to standard care.
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis
Your DNA May Explain Why Blood Thinners Work Differently for You
A meta-analysis of 39 studies involving 13,300 patients found that genetic polymorphisms (e.g., CES1, ABCB1) are associated with pharmacokin…
Tiny DNA differences may explain why the same blood thinner protects one person but causes bleeding in another.